Why Attend

The Premier Partnering Event of 2022

The 12th Annual Global Life Science Partnering Conference is returning in-person to The Lodge at Torrey Pines in February 2022. This conference is an exclusive global partnering forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. Join us February 22nd to 24th, 2022, where industry leaders will debate current trends, companies will showcase their latest technologies and all attendees will have the opportunity to schedule one-on-one meetings with leading deal-makers from around the globe.

The partnering conference and the relationships you build promise to be fruitful for your business ventures this year and for many years to come. We are excited by the prospect of continuing an annual bio-pharma partnering conference that brings together leading deal makers and emerging biotechs from around the world.

All in person attendees will be required to be fully vaccinated and provide proof of vaccination.  Please see the COVID-19 page for more detailed information.

IndustryAttendeeDemographic_GPC    RegionalDemographic_GPC

Hear What Others Have to Say:

“Every partnering meeting was great and all the panels were beyond fantastic. I even met a new investor at Biocom California’s Global Life Science Partnering Conference.”
Ross Bundy, CEO, Nanomedical Diagnostics

“Presenting at Biocom California’s Global Life Science Partnering Conference helped put Forge on the radar of several investors seeking to put money to work in the antibiotic space. The conference not only gave me the opportunity to meet the interested investors face-to-face but also gave me a platform to describe our funding strategy and growth trajectory, which gave us additional momentum leading to upsizing our Series A round. In fact, after my presentation multiple investors that were ‘circling the hoop’ were now ready to jump into the game and asked if they could participate in the Series A financing.”
Zachary Zimmerman, Ph.D., CEO , Forge Therapeutics, Inc.